PDS Biotechnology (NASDAQ:PDSB) Given New $13.00 Price Target at HC Wainwright

PDS Biotechnology (NASDAQ:PDSB) had its target price cut by HC Wainwright from $21.00 to $13.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

PDS Biotechnology Trading Up 0.8 %

NASDAQ:PDSB opened at $1.25 on Thursday. The company’s 50 day moving average is $1.41 and its 200-day moving average is $2.17. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 12 month low of $1.13 and a 12 month high of $4.56. The firm has a market cap of $47.74 million, a price-to-earnings ratio of -1.08 and a beta of 1.68.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. Equities analysts anticipate that PDS Biotechnology will post -1.2 EPS for the current year.

Institutional Trading of PDS Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in shares of PDS Biotechnology in the fourth quarter worth $26,000. Jane Street Group LLC bought a new stake in PDS Biotechnology in the 4th quarter valued at $58,000. Marshall Wace LLP grew its position in PDS Biotechnology by 38.4% in the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after purchasing an additional 10,837 shares during the last quarter. Virtu Financial LLC bought a new position in shares of PDS Biotechnology during the 4th quarter worth about $89,000. Finally, Two Sigma Investments LP raised its position in shares of PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after buying an additional 48,132 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.